Novartis’s Pluvicto Shows Promise in Prostate Cancer Treatment

Novartis ( (NVS) ) just unveiled an announcement.

On June 2, 2025, Novartis announced positive interim results from the Phase III PSMAddition trial, demonstrating that their radioligand therapy, Pluvicto, in combination with standard hormone therapy, significantly improves radiographic progression-free survival in patients with PSMA-positive metastatic hormone-sensitive prostate cancer. This marks a potential advancement in treatment options for these patients, as Pluvicto had previously been approved for metastatic castration-resistant prostate cancer. The company plans to present these findings at an upcoming medical meeting and submit them for regulatory review later this year, highlighting Novartis’s commitment to addressing unmet needs in prostate cancer treatment.

The most recent analyst rating on (NVS) stock is a Hold with a $123.50 price target. To see the full list of analyst forecasts on Novartis stock, see the NVS Stock Forecast page.

Spark’s Take on NVS Stock

According to Spark, TipRanks’ AI Analyst, NVS is a Outperform.

Novartis displays strong financial performance with robust profitability and efficient cash flow management. The positive earnings call further enhances its outlook, supported by impressive sales growth and product approvals. While the technical analysis shows mixed signals, the valuation remains reasonable, balancing growth and income potential. Challenges in product rollout and geopolitical factors are noted but do not overshadow the overall positive outlook.

To see Spark’s full report on NVS stock, click here.

More about Novartis

Novartis is a global healthcare company based in Basel, Switzerland, primarily focused on the development and manufacturing of pharmaceuticals and radioligand therapies (RLTs) for advanced cancers. The company is investing in a broad portfolio of RLTs, targeting various cancers including prostate, breast, colon, lung, and pancreatic cancers, and is expanding its manufacturing capabilities to meet growing demand.

Average Trading Volume: 2,265,102

Technical Sentiment Signal: Strong Buy

Current Market Cap: $217.8B

Find detailed analytics on NVS stock on TipRanks’ Stock Analysis page.